Diamyd – The novel vaccine for type 1 diabetes in pipeline

      Immune system-focused treatments have gained popularity due to their potential to prevent or delay the onset of type 1 diabetes. One promising development in type 1 diabetes prevention is the Diamyd vaccine. This vaccine involves injecting a small quantity of the GAD-65 protein into lymph nodes, which are small organs that house some of the body's immune cells.

      Data from the ongoing phase 2b trial, DIAGNODE-2, conducted over the past two years, have shown promise. The study involved 109 individuals between the ages of 12 and 24. The results indicate that the vaccine has the potential to improve glucose management, as measured by 'Time in Range.' Diamyd has also shown promising results in a safety study involving 14 individuals diagnosed with latent autoimmune diabetes in adults (LADA).